Dianthus Therapeutics, Inc. director Anne McGeorge reported option exercises and related sales of common stock. On August 10, 2026, she exercised options for 7,750 shares of common stock at exercise prices of $19.36 and $11.20 per share, then sold 7,750 shares in multiple transactions at weighted average prices between $106.79 and $111.63 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
Dianthus Therapeutics (DNTH) director Simon Read exercised stock options for 2,777 shares of common stock at an exercise price of $18.36 per share, converting a Stock Option (Right to Buy) into common shares. On the same date, he reported six open-market sales totaling 2,777 shares at per-share prices including $107.11, $108.17, $108.95, $109.96, $111.05 and $111.77, each disclosed as a weighted average price across multiple trades within specified ranges. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. Following the option exercise, Read reported 22,223 option shares remaining under the same award, which vests in three equal annual installments, subject to continued service and an expiration date of May 22, 2035.
Dianthus Therapeutics executive Adam M. Veness, SVP, General Counsel and Secretary, exercised 20,000 stock options at an exercise price of $17.88 per share and sold the same number of common shares in open-market transactions at prices around $110–$111 per share. The trades on August 7 and 10, 2026 were effected under a Rule 10b5-1 trading plan adopted on March 18, 2026. The options exercised are from an award vesting in equal monthly installments over four years after January 1, 2024.
A shareholder associated with ticker DNTH filed to sell common stock under Rule 144. The filing lists 16,167 common shares with an aggregate market value of $1,760,909.64, to be transacted through Morgan Stanley Smith Barney LLC Executive Financial Services on 08/10/2026 on NASDAQ. The shares relate to an exercise of stock options for cash from the issuer on the same date. Over the prior three months, 10b5-1 plan sales by Adam M. Veness included 3,833 shares for $424,317.70 on 08/07/2026 and 30,000 shares for $2,424,033.00 on 06/17/2026.
Dianthus Therapeutics CEO and President Garcia Marino reported multiple insider trades dated August 7, 2026. He exercised stock options to acquire 166,000 shares of common stock at an exercise price of $8.44 per share, then on the same date sold 166,000 common shares in a series of open‑market or private transactions at weighted average prices such as $107.49, $108.05 and $110.76 per share. Footnotes state that the reported transaction was effected under a Rule 10b5‑1 trading plan adopted on May 8, 2026, and that the options, expiring June 6, 2032, began vesting on November 1, 2022 with the remainder vesting in equal monthly installments over three years, subject to continued service.
DNTH reporting person Adam M. Veness filed to sell 3,833 shares of common stock, expected on August 7, 2026, following an exercise of stock options for cash. The filing also lists prior Rule 10b5-1 plan sales of 30,000 common shares on June 17, 2026 for $2,424,033.00.
Dnth Holdings Inc. received a notice of proposed sale of common stock under Rule 144. A broker, Morgan Stanley Smith Barney LLC Executive Financial Services, is listed to handle the potential sale of 126,000 shares of common stock on NASDAQ on or after August 7, 2026. The shares relate to an exercise of options under a registered plan. Common shares outstanding are reported as 55,934,378 as context for the size of this proposed transaction.